These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22842184)

  • 1. Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: a Phase II study.
    Salah-Eldin MA; Wahba HA; Halim AA
    Indian J Cancer; 2012; 49(1):169-75. PubMed ID: 22842184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer.
    Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Carta G; Necozione S; Mantovani G; Rea S
    Gynecol Oncol; 2007 Jul; 106(1):164-9. PubMed ID: 17481704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer.
    Nicoletto MO; Falci C; Pianalto D; Artioli G; Azzoni P; De Masi G; Ferrazzi E; Perin A; Donach M; Zoli W
    Gynecol Oncol; 2006 Feb; 100(2):318-23. PubMed ID: 16239023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
    Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
    Shoji T; Takatori E; Omi H; Kagabu M; Honda T; Futagami M; Yokoyama Y; Kaiho M; Tokunaga H; Otsuki T; Takano T; Yaegashi N; Kojimahara T; Ohta T; Nagase S; Soeda S; Watanebe T; Nishiyama H; Sugiyama T
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):355-361. PubMed ID: 28656383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
    J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
    Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
    Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
    Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
    Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
    Zelek L; Cottu P; Tubiana-Hulin M; Vannetzel JM; Chollet P; Misset JL; Chouaki N; Marty M; Gamelin E; Culine S; Dieras V; Mackenzie S; Spielmann M
    J Clin Oncol; 2002 May; 20(10):2551-8. PubMed ID: 12011135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study.
    Floquet A; Doussau A; Brouste V; Cany L; Dutin JP; Mathoulin-Pélissier S
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):61-8. PubMed ID: 24141374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.
    Ray-Coquard I; Weber B; Cretin J; Haddad-Guichard Z; Lévy E; Hardy-Bessard AC; Gouttebel MC; Geay JF; Aleba A; Orfeuvre H; Agostini C; Provencal J; Ferrero JM; Fric D; Dohollou N; Paraiso D; Salvat J; Pujade-Lauraine E;
    Br J Cancer; 2009 Feb; 100(4):601-7. PubMed ID: 19190632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
    Koinis F; Polyzos A; Christopoulou A; Zafeiriou Z; Emmanouilidis C; Papadimitraki E; Kalykaki A; Kalbakis K; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):819-25. PubMed ID: 24531559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
    Verschraegen CF; Czok S; Muller CY; Boyd L; Lee SJ; Rutledge T; Blank S; Pothuri B; Eberhardt S; Muggia F
    Ann Oncol; 2012 Dec; 23(12):3104-3110. PubMed ID: 22851407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.
    Chollet P; Bensmaïne MA; Brienza S; Deloche C; Curé H; Caillet H; Cvitkovic E
    Ann Oncol; 1996 Dec; 7(10):1065-70. PubMed ID: 9037366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
    Keller AM; Mennel RG; Georgoulias VA; Nabholtz JM; Erazo A; Lluch A; Vogel CL; Kaufmann M; von Minckwitz G; Henderson IC; Mellars L; Alland L; Tendler C
    J Clin Oncol; 2004 Oct; 22(19):3893-901. PubMed ID: 15459210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer.
    Recchia F; De Filippis S; Saggio G; Amiconi G; Cesta A; Carta G; Rea S
    Anticancer Drugs; 2003 Sep; 14(8):633-8. PubMed ID: 14501385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study.
    Skarlos DV; Kalofonos HP; Fountzilas G; Dimopoulos MA; Pavlidis N; Razis E; Economopoulos T; Pectasides D; Gogas H; Kosmidis P; Bafaloukos D; Klouvas G; Kyratzis G; Aravantinos G
    Anticancer Res; 2005; 25(4):3103-8. PubMed ID: 16080573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
    Vergote I; Finkler NJ; Hall JB; Melnyk O; Edwards RP; Jones M; Keck JG; Meng L; Brown GL; Rankin EM; Burke JJ; Boccia RV; Runowicz CD; Rose PG
    Int J Gynecol Cancer; 2010 Jul; 20(5):772-80. PubMed ID: 20973267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.